

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE: Application of Randy K. BLEDSOE et al.

Serial No.: 10/600,751

Art Unit: 1645

Filing Date: June 20, 2003

Examiner:

For:

Structure of a Glucocorticoid Receptor Ligand Binding Domain Comprising an Expanded Binding Pocket and Methods Employing Same

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

[X]	Copies of the references are enclosed							
[]	Copies of the references were submitted in parent application Serial No (37 CFR 1.98(d))							
[]	[] A copy of the International Search Report which issued on International Application No is							
submitted herewith. All of the publications cited in the International Search Report are listed								
attached form PTO-1449 and Applicants understand that copies have been supplied to the U.S.								
	Office by the International Bureau.							
[X] The Information Disclosure Statement submitted herewith is being filed within three months filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).								
OR								
[]	The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).							
[]	The Information Disclosure Statement transmitted herewith is being filed after three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but before the mailing date of either: (1) a final action under § 1.113 or (2) a notice of allowance under § 1.311, whichever occurs first.							
	[] [] [X]							

CERTIFICATE OF MAILING (37 CFR 1.8)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450.

Date: 3/12/2004

Mariorie J. Pfeiffer

Atty. Docket No. PU4803US

	[]	Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.								
	[]	Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$180.00).								
C.	[]	ne Information Disclosure Statement transmitted herewith is being filed after a final action under § 113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the sue fee. Also enclosed is a copy of the International Search Report which Issued on International ablication No.								
	In accordance with the requirements of 37 CFR 1.97(d):									
	[]	Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. [or]								
	[]	Applicant hereby certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this statement; and								
	[]	The petition fee set forth in § 1.17(i)(1) (\$180.00) is submitted herewith.								
-	-	charge any required fees to Deposit Account No.07-1392. cate copy of this paper is attached.								
		Respectfully Submitted,								
		,								

Attorney of Record: Virginia C. Bennett

Registration No. 37,092

Date: 12 Mar 04

GlaxoSmithKline

Corporate Intellectual Property

5 Moore Drive, P.O. Box 13398

Research Triangle Park, NC 27709-3398

Telephone: (919) 483-1012 Facsimile: (919) 483-7988

FORM PTUZH49 INFORMATION DISCLOSURE STATEMENT					ATTORNEY DOCKET NO.		SERIAL NO.			
INFORMA	HON	NSCLOSURE ST	AIEMENI		PU4803US APPLICANT		10/600,751			
/ 🖰		ريه			Randy K. BLEDSOE et al.					
MAR 1	7 2004	<u> </u>			FILING DATE	o ct an	GROUP			
\		₹/			June 20, 2003		1645			
7.	3.01	*/	U.S. P	OCUMENTS						
U.S. PATENT DOCUMENTS Filir										
Examiner	Examiner Patent Issue Date			Name	Class	Subclass	If Appropriate			
Initials	l	Number				<u> </u>		Appropriate		
			·							
				<u> </u>						
		<u> </u>	<u></u> _				<u>l</u>			
				ontinue on p						
		1	FOREIG	N PATENT	T DOCUMENTS	,	· · · · · · · · · · · · · · · · · · ·	T =		
		Document	Publication			l		Translation Yes No		
		Number	Date		Country	Class	Subclass	103 110		
ļ	ļ		-	'						
	<u> </u>					<u> </u>		<u> </u>		
	 									
-	-					 	-	<u> </u>		
-						<u> </u>	+	-		
								 		
	 	<u> </u>					 			
										
						<u>† </u>				
		1	Co	ontinue on p	page					
		OTHER DOCUM			Title, Journal-Date, P	age Numb	er, Etc.)			
	1.				orticoid receptor ligand			novel mode		
					nition," Cell 110(1):93					
2. Caamano et al., "The functional relevance of the heteromeric structure of corticosteroid receptors," A							s," Annal.			
	ļ	NY Acad. Sci. 740		-						
	3.				pecificity in the binding			ogen		
	4.				y 275(34) :26164-26171					
	4.				operties of recombinant hem. Molec. Biol. 37(4)			outative role		
-	5.				sp90 and hsc70 are bot			o activate		
	-				The Journal of Biologi					
		(Jul. 2000).					. ,			
	6.		tallographic struc	tures of the	ligand-binding domain	s of the and	drogen receptor	and its		
				natural ago	onist dihydrotestosteron	ie," <i>Proc</i> . λ	latl. Acad. Sci. U	ISA		
		98(9):4904-4909								
	7.		Atomic structure	of progester	rone complexed with its	receptor,"	Nature 393(668	3):392-296		
	<u> </u>	(May 1998).	01 00 1			=				
	8. Xu et al., "Binding of hsp90 to the glucocorticoid receptor requires a specific 7-amino acid sequence at the									
	amino terminus of the hormone-binding domain," <i>The Journal of Biological Chemistry</i> 273(22) :13918-13924									
<u> </u>	<u> </u>	(May 1998).		ontinue on	nage					
EXAMINER				ontinue on	page	DATEC	ONSIDERED			
	-									
					is in conformance with					
citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.										